Oncoimmune, LTD

Rockville, MD 20852

SBIR Award Summary

Total Number of Awards 15
Total Value of Awards $5.69MM
First Award Date 09/17/01
Most Recent Award Date 09/19/17

Key Personnel

Last Name Name Awards Contact
You Ming You 1
Liu Yang Liu 1
Xu Li-Hui Xu 1
Zhou Qunmin Zhou 2
Liu Xingluo Liu 1
Fang Dexing Fang 3
Zheng Xincheng Zheng 3
QIU PING QIU 2
DEVENPORT MARTIN DEVENPORT 1
DEVINE STEVEN M. DEVINE 1
REDDY PAVAN REDDY 1

15 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-14-088
Budget: 09/19/17 - 08/31/18

Project Summary/Abstract Acute graft-versus-host disease (aGVHD) is a principal contributor to transplant related mortality (TRM), and develops in approximately 60-80% of recipients receiving unrelated donor hematopoietic stem cell transplantation (HSCT) despite standard immunosuppressive prophylaxis. Thus, novel GVHD prophylaxis treatments whi...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-122
Budget: 08/01/15 - 07/31/16
PI: PING QIU

DESCRIPTION (provided by applicant): Despite the advance of antibiotics, sepsis remains a major challenge to human health as both survival and incidence of severe sepsis have been largely unchanged in the last two decades. It is therefore important to develop new therapeutic approaches. We have recently reported that bacterial sialidases may ser...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-122
Budget: 08/01/14 - 07/31/15
PI: PING QIU

DESCRIPTION (provided by applicant): Despite the advance of antibiotics, sepsis remains a major challenge to human health as both survival and incidence of severe sepsis have been largely unchanged in the last two decades. It is therefore important to develop new therapeutic approaches. We have recently reported that bacterial sialidases may ser...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-050
Budget: 09/01/11 - 02/28/13

DESCRIPTION (provided by applicant): Sepsis is one of the top leading causes of deaths for Americans and it is responsible for approximately 200,000 deaths in US annually. Despite of the advance of antibiotics and medical treatment in general, there has been no reduction in severity and death associated with the disease. Since inflammation is th...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-050
Budget: 05/01/11 - 10/31/12

DESCRIPTION (provided by applicant): Rheumatoid arthritis (RA) is among the most common autoimmune diseases. The current treatment for RA is mainly by targeting tumor-necrosis factor (TNF). Despite the remarkable efficacy, significant portion of RA patients are not responsive to this class of drugs. Therefore, there is an urgent need to develop ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-07-280
Budget: 03/01/10 - 02/29/12

DESCRIPTION (provided by applicant): The ultimate goal of our research and development program in multiple sclerosis (MS) is to develop a novel MS drug that targets CD24, a GPI-anchored surface glycoprotein that serves as a unique and critical checkpoint for MS pathogenesis. During our previous studies supported by the phase I and phase II grant...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-07-280
Budget: 03/01/09 - 02/28/10

DESCRIPTION (provided by applicant): The ultimate goal of our research and development program in multiple sclerosis (MS) is to develop a novel MS drug that targets CD24, a GPI-anchored surface glycoprotein that serves as a unique and critical checkpoint for MS pathogenesis. During our previous studies supported by the phase I and phase II grant...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-07-80
Budget: 08/01/08 - 02/28/09

DESCRIPTION (provided by applicant): The ultimate goal of our research and development program in multiple sclerosis (MS) is to develop a novel MS drug that targets CD24, a GPI-anchored surface glycoprotein that serves as a unique and critical checkpoint for MS pathogenesis. During our previous studies supported by the phase I and phase II grant...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/05 - 08/31/06

DESCRIPTION (provided by applicant): The ultimate goal of our research and development program in multiple sclerosis (MS) is to develop a novel MS drug that targets CD24, a GPI-anchored surface glycoprotein that served as a critical checkpoint for MS pathogenesis. During our previous phase I study, we have produced a fusion protein between CD24...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/20/04 - 08/31/05

DESCRIPTION (provided by applicant): The ultimate goal of our research and development program in multiple sclerosis (MS) is to develop a novel MS drug that targets CD24, a GPI-anchored surface glycoprotein that served as a critical checkpoint for MS pathogenesis. During our previous phase I study, we have produced a fusion protein between CD24...

Load More